

# AT13148

Cat# C5052 – 10 mg


Storage at -20°C

## INFORMATION

**Chemical Formula:** C<sub>17</sub>H<sub>16</sub>ClN<sub>3</sub>O**Molecular Weight:** 313.78**CAS. No:** 1056901-62-2**Purity:** >98%**Solubility:** 50 mg/ml in DMSO**Storage:** 3 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO: 1.125 g/mL at 25 °C

**Description:** AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors. AT13148 is currently being developed by Astex Pharmaceuticals. AT13148 was identified utilizing high-throughput X-ray crystallography and fragment-based lead discovery techniques. AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK and SGK substrate phosphorylation and induction of apoptosis in both a concentration and time-dependent manner in cancer cells with clinically relevant genetic defects both in vitro and in vivo. AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC50s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.

## CHEMICAL STRUCTURE



## PRODUCT USE LIMITATION

These products are intended for research use only.